REG - Symphony Environment - Positive Coronavirus test results

Symphony Environmental TechnologiesAnnouncement

14/09/2020 07:05

RNS Number : 8233Y
  
Symphony Environmental Tech. PLC
  
14 September 2020
  
 

 
 
 
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this information is considered to be in the public domain
 
14 September 2020 
SYMPHONY ENVIRONMENTAL TECHNOLOGIES PLC 
("Symphony", the "Company" or the "Group") 
 
Positive Coronavirus test results in shorter timescales
 
Symphony announced on 23 July that Eurofins Laboratories had tested Symphony's d2p masterbatch incorporated in a polyolefin film, against the bovine form of Coronavirus in accordance with International Standard, ISO 21702-2019, and found a virus reduction of 99.84% in 24 hours.
 
Symphony is now very pleased to announce the results of further Coronavirus tests at 1, 2 and 24 hours, as follows: 
 
The Institute of Biology at UNICAMP UNIVERSITY in Sao Paolo State, Brazil ("UNICAMP") has tested polyolefin films incorporating Symphony's antimicrobial d2p masterbatches, according to:
1.   ISO 21702-2019 (Measurement of Antiviral Activity on Plastics and other non-porous Surfaces)
2.   EN 14476:2013 + A2:2019 (Chemical Disinfectants and Antiseptics - Quantitative Suspension Test Method for Virucidal Activity in Medical Areas)
3.   Robert Koch Institute's and Best Laboratory Practices 
 
All tests were conducted with biological quadruplicates (four repetitions).
The virus used in the study was the BETACORONAVIRUS Cell: L929 -NCTC clone 929 [L cell, L-929, derivative of Strain L] (ATCC® CCL-1™)(same genus as SARS-CoV-1, SARS-CoV-2, MERS among others). The host cell was a 10% bovine foetal serum.
The contact testing intervals and the antiviral performance were:
A.  1 hour, 99.9% reduction
B.  2 hours 99.99% reduction
C.  24 hours 99.999% reduction
 
UNICAMP concluded in their report that "the products were shown to be virucidal, thus, we recommend the use of such products as potential virucidal agents against coronavirus."
 
It was demonstrated that the active compound was active towards the virus only, and would not harm the host cells.
 
Michael Laurier CEO said: "this is another important breakthrough for Symphony, that leads to an exciting commercial phase that will help accelerate our global sales pipeline for d2p already in development. Plastic, unlike many other materials in common use, can be given anti-microbial properties, and d2p can be included in almost all the plastic products which we touch every day.
 
"These results demonstrate the efficacy against viruses of d2p anti-microbial technology in plastic products, and the importance it has in helping governments to control the spread of the virus, and saving lives. This technology goes beyond short term protections such as washing with soap, sanitising hands, or wiping surfaces; being embedded in the plastic itself, d2p provides protection for the lifetime of the plastic product.
 
"I would like to congratulate our scientific team for developing this remarkable product that we will be moving quickly into our global sales operations." 
 
 
Information on UNICAMP UNIVERSITY
https://www.timeshighereducation.com/world-university-rankings/university-campinas  
 
 Enquiries 



Symphony Environmental Technologies Plc








Michael Laurier, CEO


Tel: +44 (0) 20 8207 5900




Ian Bristow, CFO








www.symphonyenvironmental.com


















Zeus Capital Limited (Nominated Adviser and Joint Broker)








David Foreman / Nick Cowles / Kieran Russell (Corporate Finance)


Tel: +44 (0) 161 831 1512




Dominic King / Victoria Ayton (Sales)


Tel: +44 (0) 203 829 5000














Hybridan LLP (Joint Broker) 
Claire Louise Noyce
 


 
Tel: +44 (0) 203 764 2341



The person responsible for arranging the release of this information is Michael Laurier, CEO      of the Company. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCFFFFIAFIVLII